Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:
As of 17 July 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,135,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.001% of the total share capital and 10.001% of the total voting rights in Zealand Pharma A/S.
Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V., which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk.
Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,135,191 shares (each share carrying one vote), corresponding to 10.001% of the total share capital and 10.001% of the total voting rights in Zealand Pharma A/S.
Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.
Please see further details in the attached notification forms.
# # #
About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
Contact
Adam Lange (Investors)
Vice President, Investor Relations
[email protected]
Neshat Ahmadi (Investors)
Investor Relations Manager
[email protected]
Anna Krassowska (Investors and Media)
Vice President, Investor Relations & Corporate Communications
[email protected]
Attachments
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Morning Bid: Split Bank of England set to cut rates
A look at the day ahead in European and global markets from Kevin Buckland There's little doubt in the market's mind that the Bank of England will cut interest rates later today by another quarter point, making it five cuts in the past year. But a tricky balance between a slowing jobs market and nagging inflation worries could see the board split three ways, with two of the nine members potentially pushing for no change, while two others may lobby for a half-point reduction. The board's language will also be key, with a focus on whether the message of "gradual and careful" policy easing remains in place. Any signs of an extended pause would be a blow for Finance Minister Rachel Reeves and Prime Minister Keir Starmer, who have promised to speed up Britain's slow economic growth. Away from the UK, the market's broad focus falls squarely on another central bank with some similar problems. The U.S. Federal Reserve has seen the macroeconomic data take a distinct downward turn over the past week - particularly the labour market - just days after the board opted to forgo a rate cut. But with worries about simmering inflationary forces as a result of President Donald Trump's bellicose tariff campaign also showing up in the data, Fed Chair Jerome Powell's wait-and-see stance also finds some support. Hanging over the Fed's debate - which saw two Trump-chosen Fed governors dissent in last week's decision - are the president's persistent and aggressive calls to cut rates, often framed with name-calling and threats to fire Powell before his chairmanship expires in May. The market's eyes are on Trump's short list of four possible replacements, and more immediately, his pick to fill a governor role abruptly vacated by Adriana Kugler. Meanwhile, Trump's barrage of tariff threats continues unabated, with a 100% duty on semiconductor imports and additional levies on India for importing Russian oil among the latest. Trump plans to talk to Russian President Vladimir Putin next week about ending the war in Ukraine, which is buoying the euro while injecting uncertainty into the outlook for crude oil. Overall though, the market has become more inured to the constant tariff sabre-rattling and Japan's Topix index marched to a record peak while tech-heavy Taiwan shares leapt more than 2% to the highest in over a year. Pan-European STOXX 50 futures are pointing 0.2% higher, with Wall Street futures also up by about the same amount. A strong U.S. earnings season is one reason for that. Coming up are Eli Lilly, ConocoPhillips and Warner Bros Discovery, among many others. Europe has a busy day of earnings reports as well, with Allianz, Siemens and Merck among them. On the data front, Germany has trade figures and industrial production numbers, while Britain gets a reading on house prices. Key developments that could influence markets on Thursday: -BoE policy decision -UK Halifax house prices (July) -German exports, imports, industrial production (all June) Trying to keep up with the latest tariff news? Our new daily news digest offers a rundown of the top market-moving headlines impacting global trade. Sign up for Tariff Watch here. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
5 minutes ago
- Yahoo
Wary of sticker shock, retailers clash with brands on price hikes
By Helen Reid LONDON (Reuters) -Caught between rising costs from tariffs and belt-tightening consumers, big retailers are clashing with the producers of consumer brands such as Nivea-maker Beiersdorf and brewer Heineken, as they look to avoid sticker shock that could hurt sales. The disputes - which have dented some brands' sales - underscore the challenge for consumer goods makers and sellers, with inflation and tariffs pushing up input costs and price spikes in commodities such as coffee. While pricing talks have never been easy, tariffs are escalating already high food inflation since the pandemic, making grocery bills more contentious and political as consumers grapple with a cost-of-living crisis. "We all should be very well aware of consumer budgets," Frans Muller, CEO of supermarket company Ahold Delhaize, which owns U.S. chains Food Lion, Hannaford, and Stop & Shop, told Reuters on Wednesday. He said conversations with consumer goods companies over pricing were "tight," adding that the industry's focus was on increasing sales volumes rather than increasing revenue by hiking prices. "That is the wrong way of supporting customers and the wrong way of growing the business itself." Ahold has in-house teams that track commodity, energy, and labour costs, and own-brand products it can compare with to establish whether price increases demanded by consumer brands are justified or not, Muller said. On the other side of the equation are the brands, facing higher costs that are squeezing margins. Beiersdorf CEO Vincent Warnery said on Wednesday that retailers in key markets, including Germany and France, had pushed back strongly in price talks last quarter, not only refusing price increases but asking for price reductions, and pulling products from shelves. Beiersdorf eventually agreed to a 2.6% rise, Warnery said, but delistings of some products by retailers knocked two percentage points off its sales growth in Europe in the second quarter. "There will be a lot of price changes pushed forward by consumer brands, some will be accepted by retailers and some will not," said Bobby Gibbs, a Dallas-based partner at Oliver Wyman who advises retailers and consumer goods firms. Manufacturers will find it easier to push higher prices through on products where there is brand loyalty and fewer strong private label alternatives, Gibbs said. Reuters' global tariff tracker shows at least 102 out of nearly 300 companies monitored by the tracker have announced price hikes in response to the trade war, with about 41 of them in the consumer sector. As well as tariffs, other factors like the cost of capital and labour, and commodity prices in the case of coffee and chocolate, are pushing prices up on certain products, Gibbs said. Trump has said the tariffs counter persistent U.S. trade imbalances and declining U.S. manufacturing power, and that the moves will bring jobs and investment to the nation. MORE PRICE HIKES AHEAD More price hikes are planned, particularly in the U.S. Tide detergent maker Procter & Gamble last week said it was raising prices on about a quarter of its products in the U.S. by a mid-single-digit percentage as part of efforts to mitigate the cost of higher tariffs on imported goods. That will affect pricing at Walmart, Target, and other stores. As talks heat up, more retailers could pull branded products temporarily as a negotiating tactic, as Ahold's Albert Heijn chain did this year in a dispute over price hikes by coffee roaster JDE Peet's. Dutch brewer Heineken last week said its beer sales were dented by a price dispute with European retailers. "Many retailers are getting more sophisticated in how they can measure product switching ... so they're willing to be bolder on delistings because they're able to protect sales and margin more than they would have in the past," said Gibbs. In Europe, retailers are joining forces to increase their clout in pricing talks. Carrefour said last month it had created a new European buying alliance called Concordis, along with rival group Coopérative U, and is in advanced discussions with other European retailers to expand the alliance. Supermarkets are developing more own-brand alternatives to big-name brands. Ahold has introduced 300 new own-brand products this year in its U.S. chains, and sales growth in those has outpaced the rest of the store, it said. Big brands have taken note, with P&G's Chief Financial Officer Andre Schulten saying last week that retailers have been implementing "more aggressive pricing" on own-brand products. "We see some level of pressure to drive trade down because of price promotional behaviour," he said, referring to consumers swapping to lower-priced products, adding the market would remain "volatile and challenging". Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Adecco Group Second Quarter 2025 Earnings: EPS Beats Expectations
Adecco Group (VTX:ADEN) Second Quarter 2025 Results Key Financial Results Revenue: €5.78b (down 1.2% from 2Q 2024). Net income: €58.0m (flat on 2Q 2024). Profit margin: 1.0% (in line with 2Q 2024). EPS: €0.34 (in line with 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Adecco Group EPS Beats Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Looking ahead, revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Professional Services industry in Europe. Performance of the market in Switzerland. The company's shares are down 3.5% from a week ago. Risk Analysis Be aware that Adecco Group is showing 3 warning signs in our investment analysis and 1 of those is potentially serious... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
